UCB S.A.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Bioinformatics
    • Large Molecule
    • Antisense, Oligonucleotides
  • Research, Analytical Equipment & Supplies

Other Names/Subsidiaries

  • Celltech Pharmaceutical
  • Element Genomics
  • Engage Therapeutics
  • Handl Therapeutics
  • Meizler Biopharma
  • Ra Pharmaceuticals
  • Schwarz Pharma
  • UCB Biopharma
  • Upstate Pharma
  • Zogenix
See more in Biomedtracker

Latest on UCB S.A.

In Vivo

How Charl Van Zyl Is Reimagining Lundbeck

 
• By David Wild

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy

Scrip

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 
• By Dexter Jie Yan

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Scrip

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Pink Sheet

Branded Pharma And Generics Industries At Odds Over UK VPAG Framework

 
• By Eliza Slawther and Dave Wallace

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under